BRAIN BIOTECH AG (BNN.DE) Stock Fundamental Analysis
Europe - FRA:BNN - DE0005203947 - Common Stock
2.27 EUR
+0.05 (+2.25%)
Overall BNN gets a fundamental rating of 2 out of 10. We evaluated BNN against 68 industry peers in the Chemicals industry. Both the profitability and financial health of BNN have multiple concerns. BNN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BNN had negative earnings in the past year.
In the past year BNN has reported a negative cash flow from operations.
In the past 5 years BNN always reported negative net income.
BNN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -17.27%, BNN is doing worse than 83.58% of the companies in the same industry.
BNN's Return On Equity of -227.22% is on the low side compared to the rest of the industry. BNN is outperformed by 91.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.27% | ||
| ROE | -227.22% | ||
| ROIC | N/A |
ROA(3y)-10.89%
ROA(5y)-10.5%
ROE(3y)-49.48%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BNN has a Gross Margin of 55.60%. This is amongst the best in the industry. BNN outperforms 85.07% of its industry peers.
BNN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BNN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.53%
GM growth 5Y-0.08%
2. Health
2.1 Basic Checks
BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, BNN has more shares outstanding
BNN has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.09, we must say that BNN is in the distress zone and has some risk of bankruptcy.
BNN has a worse Altman-Z score (-1.09) than 86.57% of its industry peers.
BNN has a Debt/Equity ratio of 0.74. This is a neutral value indicating BNN is somewhat dependend on debt financing.
BNN has a worse Debt to Equity ratio (0.74) than 70.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.09 |
ROIC/WACCN/A
WACC6.66%
2.3 Liquidity
A Current Ratio of 1.85 indicates that BNN should not have too much problems paying its short term obligations.
BNN has a Current ratio (1.85) which is in line with its industry peers.
BNN has a Quick Ratio of 1.30. This is a normal value and indicates that BNN is financially healthy and should not expect problems in meeting its short term obligations.
BNN has a Quick ratio of 1.30. This is in the better half of the industry: BNN outperforms 67.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.3 |
3. Growth
3.1 Past
The earnings per share for BNN have decreased strongly by -33.27% in the last year.
BNN shows a decrease in Revenue. In the last year, the revenue decreased by -4.71%.
BNN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.74% yearly.
EPS 1Y (TTM)-33.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.38%
Revenue 1Y (TTM)-4.71%
Revenue growth 3Y12.27%
Revenue growth 5Y6.74%
Sales Q2Q%0.7%
3.2 Future
The Earnings Per Share is expected to grow by 29.12% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 4.99% on average over the next years.
EPS Next Y45.61%
EPS Next 2Y30.79%
EPS Next 3Y25.75%
EPS Next 5Y29.12%
Revenue Next Year-0.63%
Revenue Next 2Y5.77%
Revenue Next 3Y6.99%
Revenue Next 5Y4.99%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BNN. In the last year negative earnings were reported.
Also next year BNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BNN's earnings are expected to grow with 25.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.79%
EPS Next 3Y25.75%
5. Dividend
5.1 Amount
BNN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BNN (10/24/2025, 7:00:00 PM)
2.27
+0.05 (+2.25%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners11.49%
Inst Owner ChangeN/A
Ins Owners51%
Ins Owner ChangeN/A
Market Cap49.60M
Revenue(TTM)53.61M
Net Income(TTM)-13658000
Analysts84.44
Price Target5.73 (152.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.75%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-86.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS2.45
BVpS0.28
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.27% | ||
| ROE | -227.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.6% | ||
| FCFM | N/A |
ROA(3y)-10.89%
ROA(5y)-10.5%
ROE(3y)-49.48%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.53%
GM growth 5Y-0.08%
F-Score2
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 31.1% | ||
| Cap/Sales | 2.87% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z | -1.09 |
F-Score2
WACC6.66%
ROIC/WACCN/A
Cap/Depr(3y)77.56%
Cap/Depr(5y)65.96%
Cap/Sales(3y)6.63%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.38%
EPS Next Y45.61%
EPS Next 2Y30.79%
EPS Next 3Y25.75%
EPS Next 5Y29.12%
Revenue 1Y (TTM)-4.71%
Revenue growth 3Y12.27%
Revenue growth 5Y6.74%
Sales Q2Q%0.7%
Revenue Next Year-0.63%
Revenue Next 2Y5.77%
Revenue Next 3Y6.99%
Revenue Next 5Y4.99%
EBIT growth 1Y-106.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year269.39%
EBIT Next 3Y86.79%
EBIT Next 5Y71.06%
FCF growth 1Y37.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.57%
OCF growth 3YN/A
OCF growth 5YN/A
BRAIN BIOTECH AG / BNN.DE FAQ
What is the fundamental rating for BNN stock?
ChartMill assigns a fundamental rating of 2 / 10 to BNN.DE.
What is the valuation status of BRAIN BIOTECH AG (BNN.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to BRAIN BIOTECH AG (BNN.DE). This can be considered as Overvalued.
Can you provide the profitability details for BRAIN BIOTECH AG?
BRAIN BIOTECH AG (BNN.DE) has a profitability rating of 1 / 10.
What is the financial health of BRAIN BIOTECH AG (BNN.DE) stock?
The financial health rating of BRAIN BIOTECH AG (BNN.DE) is 3 / 10.